Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know

Journal of the American College of Cardiology

Volumn 67, Issue 12, 2016, Pages 1488-1496

  Waldrop, Greer ^a   Zhong, Jixin ^a   Peters, Matthew ^a   Rajagopalan, Sanjay ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular outcomes; dipeptidyl peptidase 4; glucagon like peptide 1 receptor agonist

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; BASAL INSULIN; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIPOPROTEIN; LIRAGLUTIDE; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SHORT ACTING DRUG; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; GLUCOSE BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DEGRADATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE REACTION; INSULIN RELEASE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84962332896     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.058     Document Type: Review

References (67)

1. Emerging Risk Factors Collaboration Association of cardiometabolic multimorbidity with mortality JAMA 314 2015 52 60
2. R.E. Gilbert, and H. Krum Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy Lancet 385 2015 2107 2117
3. G.P. Fadini, A. Avogaro, L. Degli Esposti, et al. for the OsMed Health-DB Network Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database Eur Heart J 36 2015 2454 2462
4. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 124 2011 S3 S18
5. E.E. Mulvihill, and D.J. Drucker Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr Rev 35 2014 992 1019
6. M. Shigeto, R. Ramracheya, A.I. Tarasov, and et al. GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation J Clin Invest 125 2015 4714 4728
7. J.G. Barrera, D.A. Sandoval, D.A. D'Alessio, and et al. GLP-1 and energy balance: an integrated model of short-term and long-term control Nat Rev Endocrinol 7 2011 507 516
8. J. Zhong, A. Maiseyeu, S.N. Davis, and et al. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition Circ Res 116 2015 1491 1504
9. R.E. Pratley, M. Nauck, T. Bailey, et al. for the 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456
10. D. Russell-Jones, R.M. Cuddihy, M. Hanefield, et al. for the DURATION-4 Study Group Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 35 2012 252 258
11. M. Nauck, R.S. Weinstock, G.E. Umpierrez, and et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care 37 2014 2149 2158
12. B. Ahrén, S.L. Johnson, M. Stewart, et al. for the HARMONY 3 Study Group HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 37 2014 2141 2148
13. B. Gallwitz, J. Guzman, F. Dotta, and et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial Lancet 379 2012 2270 2278
14. M. Marre, J. Shaw, M. Brändle, et al. for the LEAD-1 SU Study Group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 26 2009 268 278
15. R.M. Bergenstal, C. Wysham, L. MacConell, et al. for the DURATION-2 Study Group Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
16. G. Umpierrez, S. Tofé Povedano, F. Pérez Manghi, and et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 37 2014 2168 2176
17. T. Vilsbøll, M. Christensen, A.E. Junker, and et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
18. N. Inagaki, Y. Atsumi, T. Oura, and et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clin Ther 34 2012 1892 1908
19. M. Nauck, E. Horton, M. Andjelkovic, et al. for the T-Emerge 5 Study Group Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial Diabet Med 30 2013 109 113
20. M. Diamant, L. Van Gaal, S. Stranks, and et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 375 2010 2234 2243
21. P.N. Weissman, M.C. Carr, J. Ye, and et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 57 2014 2475 2484
22. M. Davies, S. Heller, S. Sreenan, and et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas Diabetes Care 36 2013 1368 1376
23. Y. Seino, K.W. Min, E. Niemoeller, et al. for the GetGoal-L-Asia Study Investigators Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes Obes Metab 14 2012 910 917
24. J.B. Buse, R.M. Bergenstal, L.C. Glass, and et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 154 2011 103 112
25. T. Karagiannis, P. Paschos, K. Paletas, and et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 2012 e1369
26. P. Aschner, H.L. Katzeff, H. Guo, and et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes Diabetes Obes Metab 12 2010 252 261
27. M. Jadzinsky, A. Pfützner, E. Paz-Pacheco, et al. for the CV181-039 Investigators Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial Diabetes Obes Metab 11 2009 611 622
28. R. Arechavaleta, T. Seck, Y. Chen, and et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 13 2011 160 168
29. C. Filozof, and J.F. Gautier A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study Diabet Med 27 2010 318 326
30. D.R. Matthews, S. Dejager, B. Ahren, and et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study Diabetes Obes Metab 12 2010 780 789
31. T. Seck, M. Nauck, D. Sheng, et al. for the Sitagliptin Study 024 Group Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study Int J Clin Pract 64 2010 562 576
32. A.R. Chacra, G.H. Tan, S. Ravichandran, et al. for the CV181040 Investigators Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks Diab Vasc Dis Res 8 2011 150 159
33. B. Gallwitz, J. Rosenstock, T. Rauch, and et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 380 2011 475 483
34. B. Göke, B. Gallwitz, J.G. Eriksson, and et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial Int J Clin Pract 67 2013 307 316
35. G. Schernthaner, J.L. Gross, J. Rosenstock, and et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 2013 2508 2515
36. T. Vilsbøll, J. Rosenstock, H. Yki-Järvinen, and et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 12 2010 167 177
37. H. Yki-Jarvinen, J. Rosenstock, S. Duran-Garcia, and et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study Diabetes Care 36 2013 3875 3881
38. P. Aschner, J. Chan, D.R. Owens, et al. for the EASIE Investigators Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial Lancet 379 2012 2262 2269
39. J. Rosenstock, V. Fonseca, J.L. Gross, et al. for the Harmony 6 Study Group Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro Diabetes Care 37 2014 2317 2325
40. Philis-Tsimikas, S. Del Prato, I. Satman, and et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents Diabetes Obes Metab 15 2013 760 766
41. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed January 18, 2016.
42. B. Eliasson, D. Möller-Goede, K. Eeg-Olofsson, and et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia 55 2012 915 925
43. M.J. Davies, R. Bergenstal, B. Bode, et al. for the NN8022-1922 Study Group Efficacy of liraglutide for weight loss among patients with type 2 diabetes JAMA 314 2015 687 699
44. D. Russell-Jones, A. Vaag, O. Schmitz, et al. for the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 52 2009 2046 2055
45. M. Katout, H. Zhu, J. Rutsky, and et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression Am J Hypertens 27 2014 130 139
46. L.E. Robinson, T.A. Holt, K. Rees, and et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis BMJ Open 3 2013 e001986
47. C. Wysham, T. Blevins, R. Arakaki, and et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 37 2014 2159 2167
48. K.C. Ferdinand, W.B. White, D.A. Calhoun, and et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus Hypertension 64 2014 731 737
49. M. Kim, M.J. Platt, T. Shibasaki, and et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nat Med 19 2013 567 575
50. J.A. Lovshin, A. Barnie, A. DeAlmeida, and et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes Diabetes Care 38 2015 132 139
51. D.J. Drucker, J.B. Buse, K. Taylor, et al. for the DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
52. J.B. Buse, J. Rosenstock, G. Sesti, et al. for the LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
53. B.M. Scirica, D.L. Bhatt, E. Braunwald, et al. for the SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
54. W.B. White, C.P. Cannon, S.R. Heller, et al. for the EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 2013 1327 1335
55. J.B. Green, M.A. Bethel, P.W. Armstrong, and et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 2015 232 242
56. M.A. Pfeffer, B. Claggett, R. Diaz, et al. for the ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2015 2247 2257
57. F. Zannad, C.P. Cannon, W.C. Cushman, et al. for the EXAMINE Investigators Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet 6736 2015 1 10
58. A. Garber, J.E. Foley, M.A. Banerji, and et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea Diabetes Obes Metab 10 2008 1047 1056
59. R.G. Moses, S. Kalra, D. Brook, and et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea Diabetes Obes Metab 16 2014 443 450
60. J.B. Buse, M. Nauck, T. Forst, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
61. K.M. Dungan, S.T. Povedano, T. Forst, and et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 384 2014 1349 1357
62. R.E. Pratley, M.A. Nauck, A.H. Barnett, et al. for the HARMONY 7 Study Group Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 2014 289 297
63. A.G. Egan, E. Blind, K. Dunder, and et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment [published correction appears in N Engl J Med 2014;370:2253] N Engl J Med 370 2014 794 797
64. R.R. Holman, H. Sourij, and R.M. Califf Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes Lancet 383 2014 2008 2017
65. S. Vijan, J.B. Sussman, J.S. Yudkin, and et al. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus JAMA Intern Med 174 2014 1227 1234
66. J. Zhong, A. Goud, and S. Rajagopalan Glycemia lowering and risk for heart failure: recent evidence from studies of dipeptidyl peptidase inhibition Circ Heart Fail 8 2015 819 825
67. J. Zhong, A. Maiseyeu, and S. Rajagopalan Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors Clin Lipidol 10 2015 103 112